Abstract
Seven randomized clinical trials have tested the use of moderate hypofractionation (2.1-3.5 Gy per fraction) compared to conventional fractionation (1.8-2.0 Gy per fraction) in radiotherapy for localized prostate cancer. The trails find that moderate hypofractionation results in acceptable PSA-control and morbidities that are comparable to conventional fractionation schedules. Extrapolation of the results from the earliest randomized trials indicated a low α/β- values for prostate cancer, but the more recent – and large – studies suggest that the value is moderately or considerably higher. Moderate hypofractionation schedules (ie. 20 x 3 Gy) are now being implemented in routine practice. They are cost-effective and convinient, but they are not consistantly concordant with fractionation sensitivity parameters extrapolated from clinical trials on moderate hypofractionation of prostate cancer.
Export citation and abstract BibTeX RIS
Content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.